A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
Clinical trial NCT07003074 · RECRUITING
Trial details
- NCT number
- NCT07003074
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-06-23
- Primary completion
- 2029-07-01
- Enrollment
- 642
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.